Asset
Cadisegliatin
vTv Therapeutics Inc. Class A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02405260 | phase2 | completed | 2015-03-01 | 2016-07-01 | vTv Therapeutics | Add Glucokinase Activator to Target A1c |
| NCT03335371 | phase1_2 | completed | 2017-10-25 | 2019-12-20 | vTv Therapeutics | Evaluation of TTP399 in Patients With Type 1 Diabetes |
FDA applications (0)
This company has no applications containing this asset.